Market capitalization | $991.96m |
Enterprise Value | $589.55m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.03 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-384.66m |
Free Cash Flow (TTM) Free Cash Flow | $-367.84m |
Cash position | $439.96m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
11 Analysts have issued a 89bio Inc forecast:
11 Analysts have issued a 89bio Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.04 -0.04 |
69%
69%
|
|
EBITDA | -385 -385 |
155%
155%
|
EBIT (Operating Income) EBIT | -385 -385 |
154%
154%
|
Net Profit | -367 -367 |
158%
158%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Rohan Palekar |
Employees | 93 |
Founded | 2018 |
Website | www.89bio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.